Skip to main content
Viatris10-Q: Litigation material

Viatris in dispute with Pfizer over liability payments for opioid litigation.

What happened

Viatris is disputing a payment request from Pfizer related to a 57% share of opioid-related losses. This significant legal and financial conflict could drive spending on e-discovery, legal services, and risk management solutions.

Source

SEC EDGARAug 6, 2026

Quarterly report (Form 10-Q)

Viatris 10-Q

Filing excerpt

Viatris agreed to pay Pfizer an amount equal to 57% of any losses actually incurred or suffered by Viatris, its predecessors or subsidiaries, since July 29, 2019, arising out of third-party actions relating to the manufacture, distribution, marketing, promotion or sale of opioids by or on behalf of Viatris, its predecessors or subsidiaries.

sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htmRead the full source

Other signals in this filing (6)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Litigation material

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
06/30
Filed
Aug 6, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
57% (Share of opioid-related losses Viatris agreed to pay Pfizer, which is now in dispute.)

Details

CIK
1792044
Accession number
0001792044-26-000041
Timeframe
Current quarter
Filing year
2026
Fiscal year
0
Why it matters
Legal tech opportunity
Signal category
Risk

Topics and mentions

Competitors

  • Pfizer

Extraction

Confidence
High
Relevance
90%
Sentiment
Negative
Detected
Aug 11, 2026
signal_type
sec-10q
signal_subtype
litigationMaterial

Use this data

Get every 10-Q signal for Viatris and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Viatris this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/8fa11444-22b2-43b5-a4dc-1fd5c8a56b10 returns this record as JSON. POST /v1/companies/enrich returns every signal for viatris.com.

{
  "signal_id": "8fa11444-22b2-43b5-a4dc-1fd5c8a56b10",
  "signal_type": "sec-10q",
  "signal_subtype": "litigationMaterial",
  "detected_at": "2026-08-11T08:09:21.892+00:00",
  "company": {
    "name": "Viatris",
    "domain": "viatris.com"
  },
  "data": {
    "detail": "Viatris is disputing a payment request from Pfizer related to a 57% share of opioid-related losses. This significant legal and financial conflict could drive spending on e-discovery, legal services, and risk management solutions.",
    "metrics": {
      "pct": 0.57,
      "timeframe": "current_quarter",
      "pct_context": "Share of opioid-related losses Viatris agreed to pay Pfizer, which is now in dispute."
    },
    "summary": "Viatris in dispute with Pfizer over liability payments for opioid litigation.",
    "excerpts": "Viatris agreed to pay Pfizer an amount equal to 57% of any losses actually incurred or suffered by Viatris, its predecessors or subsidiaries, since July 29, 2019, arising out of third-party actions relating to the manufacture, distribution, marketing, promotion or sale of opioids by or on behalf of Viatris, its predecessors or subsidiaries.",
    "relevance": 0.9,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htm",
    "filing_date": "2026-08-06",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Legal tech opportunity",
    "signal_category": "risk",
    "competitors_mentioned": [
      "Pfizer"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.